Skip to main content
LLY
NYSE Life Sciences

FDA Expands Jaypirca Label to First-Line CLL/SLL, Unlocking Major Market

Tom Rudovsky · Reported by PR Newswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,147.3
Mkt Cap
$1.08T
52W Low
$783.845
52W High
$1,292.65
52W Position info
46% above low
Off High info
11% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

LLY sits 46% above its 52-week low of $783.845.

Summary

The FDA expanded Jaypirca's indication to include previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), making it the first non-covalent BTK inhibitor approved in the first-line setting. This significantly broadens the addressable patient population beyond the relapsed/refractory setting where Jaypirca was previously approved. The approval follows Lilly's strong Q2 results and recent pipeline momentum, including positive data for EloraTZP and retatrutide. Jaypirca's first-line approval positions it to compete directly with established covalent BTK inhibitors like ibrutinib and acalabrutinib, potentially driving meaningful revenue growth. Watch for Lilly's commentary on launch strategy and pricing in the upcoming earnings call.

At the time of this announcement, LLY was trading at $1,147.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $783.85 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,416.23 info
Change: -$39.13 (-3%) info
Market Cap: $1.332T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,416.23 info
Change: -$36.47 (-3%) info
Market Cap: $1.332T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,416.23 info
Change: -$31.63 (-2%) info
Market Cap: $1.332T info
LLY
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,411.12
Real-time Price: $1,416.23 info
Change: +$5.11 (+0.36%) info
Market Cap: $1.332T info
LLY
Nov 09, 2026, 10:23 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1,394.15
Real-time Price: $1,416.23 info
Change: +$22.07 (+2%) info
Market Cap: $1.332T info